Related Experiment Video

Updated: May 29, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K

Early Experience on Universal Prophylaxis in Infants against Respiratory Syncytial Virus: Facts and Expectations

Antoni Soriano-Arandes1,2, Anna Creus-Costa2,3, Aida Perramon-Malavez4

  • 1Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Seminars in Respiratory and Critical Care Medicine
|February 3, 2025
PubMed

Insights

Nirsevimab significantly lowered the risk of respiratory syncytial virus (RSV) infections and hospitalizations in infants during the 2023/24 season. This immunization offers a transformative approach to reducing the global burden of RSV in infants.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • Respiratory syncytial virus (RSV) poses a significant health threat to infants globally.
  • Bronchiolitis and RSV infections lead to substantial primary care, hospital, and pediatric intensive care unit admissions.

Purpose of the Study:

  • To evaluate the effectiveness of nirsevimab in reducing RSV-related outcomes in infants aged 0 to 11 months.
  • To assess the impact of nirsevimab during a season with a high community RSV burden.

Main Methods:

  • Observational study during the 2023/24 season.
  • Analysis of nirsevimab's impact on bronchiolitis and confirmed RSV infections.
  • Assessment across different care settings (primary care, hospital, PICU).

Main Results:

  • Nirsevimab significantly reduced the risk of RSV infections and related hospital admissions in infants.
  • Effectiveness was observed even during a high RSV season, particularly in older infants.
  • Demonstrated utility for public health authorities in guiding immunization strategies.

Conclusions:

  • Universal immunization with nirsevimab is a transformative strategy for reducing infant RSV burden.
  • High expectations for reduced RSV hospitalizations and improved public health outcomes.
  • Addressing challenges in vaccine uptake, funding, and surveillance is crucial for widespread success.

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.1K

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
282
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Standard Precaution01:26

Standard Precaution

Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
1.8K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
224
Vaccinations01:51

Vaccinations

Overview
43.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
4.9K